Wednesday, January 16, 2013

Pharma is on the rebound - what factors are playing to this?

Over the past few decades, Pharma has seen a big change in the way from who can afford to buy their services to finding ways to overcome the patent cliff of 2012.  In a recent interview at Financial Times, Stuart Kirk and Vincent Boland of Lex discussed the potential of brighter times in Pharma's future.  There is more potential for drug approvals coming out of the regulatory agencies.  There is also massive expansion into emerging markets, with everything from production of the products to conducting clinical trials.

What Pharma is still challenged with is the current unproductive process that research and development sees.  They discuss this more in the video.  Watch the full discussion here.

One of the large parts of clinical expansion is the clinical trials piece for Pharma. It can be a challenge to adopt to the new markets and cultures that come with operating in these new countries. This April at Partnerships in Clinical Trials, representatives from Merck and PAREXEL International will be joining us to talk about the adaption process for large Pharma in the presentation "Adapting Strategic Partnerships to the Needs of Emerging Markets." For more information on this session and the rest of the agenda, download the brochure. If you'd like to join us in Orlando, as a reader of this blog, when you register to join us and mention code XP1800BLOG, save 15% off the standard rate.

How can Pharma work with emerging markets to find a better, more productive  research and development process?

No comments: